AR031379A1 - Derivados indoloquinazolin-5-onas, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la fabricacion de dichos medicamentos - Google Patents

Derivados indoloquinazolin-5-onas, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la fabricacion de dichos medicamentos

Info

Publication number
AR031379A1
AR031379A1 ARP010103339A ARP010103339A AR031379A1 AR 031379 A1 AR031379 A1 AR 031379A1 AR P010103339 A ARP010103339 A AR P010103339A AR P010103339 A ARP010103339 A AR P010103339A AR 031379 A1 AR031379 A1 AR 031379A1
Authority
AR
Argentina
Prior art keywords
alkyl
derivatives
cycloalkyl
indoloquinazolin
manufacture
Prior art date
Application number
ARP010103339A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR031379A1 publication Critical patent/AR031379A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
ARP010103339A 2000-07-17 2001-07-13 Derivados indoloquinazolin-5-onas, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la fabricacion de dichos medicamentos AR031379A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0017508.3A GB0017508D0 (en) 2000-07-17 2000-07-17 Antimicrobials

Publications (1)

Publication Number Publication Date
AR031379A1 true AR031379A1 (es) 2003-09-24

Family

ID=9895801

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103339A AR031379A1 (es) 2000-07-17 2001-07-13 Derivados indoloquinazolin-5-onas, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la fabricacion de dichos medicamentos

Country Status (18)

Country Link
US (1) US6964960B2 (enExample)
EP (1) EP1303517B1 (enExample)
JP (1) JP3939246B2 (enExample)
CN (1) CN1183136C (enExample)
AR (1) AR031379A1 (enExample)
AT (1) ATE262530T1 (enExample)
AU (1) AU2001279754A1 (enExample)
BR (1) BR0112521A (enExample)
CA (1) CA2415683C (enExample)
DE (1) DE60102473T2 (enExample)
DK (1) DK1303517T3 (enExample)
ES (1) ES2218439T3 (enExample)
GB (1) GB0017508D0 (enExample)
MY (1) MY133969A (enExample)
PE (1) PE20020210A1 (enExample)
PT (1) PT1303517E (enExample)
TR (1) TR200401026T4 (enExample)
WO (1) WO2002006284A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
KR20050118169A (ko) 2003-02-28 2005-12-15 이노텍 파마슈티컬스 코포레이션 사환식 벤즈아미드 유도체 및 이것의 사용 방법
JP2008531562A (ja) 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環アミノ化合物および四環カルボキサミド化合物およびこれらの使用法
RU2008110955A (ru) 2005-08-24 2009-09-27 Инотек Фармасьютикалз Корпорейшн (Us) Инденоизохинолиноновые аналоги и способы их применения
MX2008016339A (es) 2006-06-20 2009-01-16 Abbott Lab Pirazoloquinazolinonas en la forma de inhibidores parp.
GB0615809D0 (en) * 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
KR20090115879A (ko) 2007-02-28 2009-11-09 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체와 이의 이용 방법
NZ580982A (en) 2007-05-08 2012-05-25 Schering Corp Methods of treatment using intravenous formulations comprising temozolomide
KR20140036312A (ko) * 2011-07-13 2014-03-25 산텐 세이야꾸 가부시키가이샤 Parp 저해 활성을 갖는 신규 화합물
CN102766144B (zh) * 2012-07-10 2014-04-23 浙江大学 一种吲哚并[1,2-c]喹唑啉化合物的制备方法
ES2879434T3 (es) 2015-07-23 2021-11-22 Inst Curie Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
US20220073531A1 (en) * 2018-11-30 2022-03-10 Merck Patent Gmbh Compounds for electronic devices
EP3938367A1 (de) * 2019-03-12 2022-01-19 Merck Patent GmbH Materialien für organische elektrolumineszenzvorrichtungen
CN110357892B (zh) * 2019-07-10 2022-06-07 云南大学 四氢嘧啶并[1,2-a]吲哚衍生物及其合成方法与应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN114195789B (zh) * 2021-12-15 2022-09-09 广东海洋大学 一种无金属参与的多环吲哚衍生物的制备方法
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635966A (en) 1969-10-22 1972-01-18 Robins Co Inc A H 6-substituted-indolo(1 2-c)quinazolines
DE2237372C3 (de) 1972-07-29 1981-07-09 Basf Ag, 6700 Ludwigshafen Heterocyclische Farbstoffe, ihre Herstellung und ihre Verwendung
US5441955A (en) 1993-11-19 1995-08-15 Pathogenesis Corporation Indolo[2,1-biquinazoline-6,12-dione antibacterial compounds and methods of use thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues

Also Published As

Publication number Publication date
PE20020210A1 (es) 2002-04-04
CN1441803A (zh) 2003-09-10
MY133969A (en) 2007-11-30
US6964960B2 (en) 2005-11-15
BR0112521A (pt) 2003-07-01
GB0017508D0 (en) 2000-08-30
TR200401026T4 (tr) 2004-07-21
DK1303517T3 (da) 2004-06-21
ES2218439T3 (es) 2004-11-16
DE60102473D1 (de) 2004-04-29
HK1056872A1 (en) 2004-03-05
AU2001279754A1 (en) 2002-01-30
WO2002006284A1 (en) 2002-01-24
PT1303517E (pt) 2004-07-30
CA2415683A1 (en) 2002-01-24
CN1183136C (zh) 2005-01-05
JP3939246B2 (ja) 2007-07-04
HK1055426A1 (en) 2004-01-09
EP1303517B1 (en) 2004-03-24
US20030199502A1 (en) 2003-10-23
CA2415683C (en) 2009-12-29
ATE262530T1 (de) 2004-04-15
JP2004504323A (ja) 2004-02-12
DE60102473T2 (de) 2005-02-03
EP1303517A1 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
PE20050222A1 (es) Compuestos de triazol como antagonistas de vasopresina
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
BRPI0110955B8 (pt) derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos.
UY27740A1 (es) Nuevos compuestos
EA200600497A1 (ru) Композиция для аэрозольной ингаляции, содержащая антихолинергическое средство
UY30440A1 (es) Nuevos compuestos
SV2005002102A (es) Compuestos de metil-aril o heteroaril-amida sustituida ref. pc32241a
ECSP034534A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
AR029373A1 (es) Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas
CO4970807A1 (es) Compuestos de indol 2,3 sustituidos como agentes anti-infla matorios y analgesicos
NO2011018I1 (no) Eribulin og farmasøytisk akseptable salter derav
BRPI0308513B8 (pt) micronizado cristalino de brometo de tiotrópio, processo para sua preparação, uso do mesmo, composição farmacêutica, pó para inalação, processo para sua preparação e cápsula que o contém
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
SE9904507D0 (sv) New compounds
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
AR037521A1 (es) Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion
SE0002476D0 (sv) New compounds
AR036351A1 (es) Isoxazolopiridinonas, el uso de las mismas para la fabricacion de un medicamento, composiciones y combinaciones farmaceuticas
AR032358A1 (es) Compuestos inhibidores del transporte de glicina, composicion farmaceutica y el uso de dichos compuestos para la fabricacion de un medicamento
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
EA200101230A1 (ru) Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции
SE0102057D0 (sv) New Salts I
EA200000068A2 (ru) Новые цианоиндольные соединения, являющиеся ингибиторами повторного захвата серотонина, способ их получения и фармацевтические композиции, содержащие их
SE0104333D0 (sv) Therapeutic agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal